Hikma Pharmaceuticals PLC
Voting Results of 2019 Annual General Meeting
LONDON, 17 May 2019 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 17 May 2019 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 16 were passed as ordinary resolutions and Resolutions 17 to 20 were passed as special resolutions.
Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm
The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 15 April 2019) is set out below. The number of Ordinary Shares in issue on 17 May 2019 was 242,013,996.
|
Resolution |
Votes For |
% |
Votes Against |
% |
Total Cast |
Withheld |
|
1. To receive the 2018 report and accounts |
198,016,257 |
99.99 |
15,248 |
0.01 |
198,031,505 |
145,325 |
|
2. To approve a final dividend of 26 cents per share |
198,172,485 |
100.00 |
437 |
0.00 |
198,172,922 |
3,909 |
|
3. To re-appoint PricewaterhouseCoopers LLP as auditors |
198,168,429 |
100.00 |
2,171 |
0.00 |
198,170,600 |
6,231 |
|
4.To authorise the Audit Committee to determine the auditors' remuneration |
198,169,496 |
100.00 |
1,989 |
0.00 |
198,171,485 |
5,346 |
|
5. To re-elect Said Darwazah as a director |
191,458,492 |
96.61 |
6,712,792 |
3.39 |
198,171,284 |
5,546 |
|
6. To re-elect Siggi Olafsson as a director |
194,921,594 |
98.36 |
3,251,178 |
1.64 |
198,172,772 |
4,059 |
|
7. To re-elect Mazen Darwazah as a director |
191,501,356 |
96.63 |
6,670,679 |
3.37 |
198,172,035 |
4,796 |
|
8. To re-elect Robert Pickering as a director |
186,397,645 |
94.06 |
11,763,463 |
5.94 |
198,161,108 |
15,722 |
|
9.To re-elect Ali Al-Husry as a director |
189,606,735 |
95.68 |
8,564,549 |
4.32 |
198,171,284 |
5,546 |
|
10. To re-elect Patrick Butler as a director |
194,287,800 |
98.04 |
3,883,484 |
1.96 |
198,171,284 |
5,546 |
|
11. To re-elect Dr. Pamela Kirby as a director |
182,139,906 |
91.91 |
16,032,128 |
8.09 |
198,172,034 |
4,796 |
|
12. To re-elect Dr. Jochen Gann as a director |
194,395,430 |
98.09 |
3,775,854 |
1.91 |
198,171,284 |
5,546 |
|
13. To re-elect John Castellani as a director |
195,035,397 |
98.42 |
3,135,888 |
1.58 |
198,171,285 |
5,546 |
|
14. To re-elect Nina Henderson as a director |
194,490,204 |
98.14 |
3,681,830 |
1.86 |
198,172,034 |
4,796 |
|
15. To approve the remuneration report for the year ended 31 December 2018 |
190,476,075 |
96.12 |
7,695,409 |
3.88 |
198,171,484 |
5,346 |
|
16. Authority to allot shares |
168,835,150 |
85.20 |
29,337,771 |
14.80 |
198,172,921 |
3,909 |
|
17. To dis-apply pre-emption rights for general purposes |
198,116,024 |
99.97 |
56,161 |
0.03 |
198,172,185 |
4,646 |
|
18. To dis-apply pre-emption rights for an acquisition or other capital investment |
195,242,802 |
98.52 |
2,929,382 |
1.48 |
198,172,184 |
4,646 |
|
19. To authorise the Company to purchase its own shares |
197,396,007 |
99.66 |
682,740 |
0.34 |
198,078,747 |
98,083 |
|
20. To authorise the Company to hold general meetings on no less than 14 clear days' notice |
187,234,093 |
94.48 |
10,936,803 |
5.52 |
198,170,896 |
5,785 |
Declaration of final dividend
The dividend of 26 cents per share will be paid on 22 May 2019 to shareholders on the register on 5 April 2019. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.2928 to £1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.
- ENDS -
Enquiries:
|
Hikma Pharmaceuticals PLC |
|
|
Peter Speirs Company Secretary
|
+44 20 7399 2670 |
|
Susan Ringdal EVP, Strategic Planning and Global Affairs
|
+44 20 7399 2670
|
About Hikma
Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.
LEI: 549300BNS685UXH4JI75
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
